| Today's Big NewsJun 12, 2023 |
| By Angus Liu Bayer recently laid out its ambition to achieve $10 billion in sales from its oncology business by 2030 and become a top 10 cancer drug player. To get there, the company is looking outside for a “midsize acquisition,” Bayer’s oncology chief Christine Roth said. |
|
|
|
By Nick Paul Taylor Novartis wants to give a $3.2 billion lift to its kidney disease pipeline. While working to generate phase 3 data on its own IgA nephropathy candidate, the Swiss drugmaker has seized the chance to buy Chinook Therapeutics for a pair of late-stage programs targeting the rare, progressive chronic kidney disease. |
By Ayla Ellison Francis deSouza has resigned as CEO and director of Illumina after recently surviving activist investor Carl Icahn’s proxy fight against the company, which involved demands to remove deSouza from the DNA sequencing company’s board and replace him as chief executive. |
By Kevin Dunleavy Novo Nordisk has earmarked a 15.9 billion Danish kroner ($2.3 billion) investment to expand manufacturing at its site in Hillerod, Denmark, the company revealed Monday. But it’s not what you might think. While Novo is dealing with overwhelming demand for its diabetes and obesity products Ozempic and Wegovy, this funding will expand its ability to manufacture active pharmaceutical ingredients to support its pipeline. |
|
Wednesday, June 28, 2023 11:00am ET / 8:00am PT Join us for this this insightful webinar to learn how antibody profiling has been used to successfully identify novel diagnostic, prognostic, therapeutic, and predictive biomarkers in melanoma, prostate cancer, breast cancer, ovarian cancer, and rare cancers, yielding promising results.
|
|
By Annalee Armstrong Patients with the inflammatory disorder hereditary angioedema who took Intellia Therapeutics’ CRISPR medicine have been attack free for a year or more after receiving just one dose. |
By Kevin Dunleavy After three delays, Catalent has finally released its quarterly earnings. In the end, the news wasn’t nearly as bad as expected. The CDMO giant, which has been plagued by major production problems at three of its sites, has made a slight adjustment to its revenue projection, which is expected to come in at between $4.23 billion and $4.33 billion as opposed to a previous projection window of $4.25 billion to $4.35 billion. |
By Andrea Park No more beating around the bush here: With a newly bestowed FDA clearance, Huma’s disease-agnostic health management software can now be more direct in offering clinical recommendations to users and their doctors. |
By James Waldron A week after Oncorus shed pretty much all its staff, the board has decided that the game is up and moved to liquidate the RNA-focused company. |
By Zoey Becker The drugmaker will defend itself against claims from a German healthcare worker who sued the company for at least 150,000 euros ($161,500). The plaintiff alleges she suffered bodily harm resulting from Pfizer and BioNTech's Comirnaty vaccine. |
By Nick Paul Taylor Coya Therapeutics’ plan to treat frontotemporal dementia by boosting the function of regulatory T cells is unraveling. Months after putting FTD at the heart of its IPO pitch, the biotech has decided it would be “premature” to continue to study its low-dose formulation of IL-2 in the indication. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss the the top news from this year's annual ASCO meeting, plus contesting the Inflation Reduction Act, an ADHD video game, and the rest of the week's headlines. |
|
|---|
|
|
|
Monday, Jun 26, 2023 | 11:00 am ET Join us for a webinar on “The RESTORE Trial: First-Ever Lab-Grown RBCs” where Dr. Ashley Toye will talk about the first-ever clinical trial conducted for the transfusion of lab-grown red blood cells. Register now. |
|
| WhitepaperAutoantibody screening is promising for early cancer detection with the potential to improve the whole treatment decision tree, providing a less invasive, powerful approach. Sponsored by: Sengenics |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| eBookSee how clinical trial sponsors can build stronger strategies to address challenges across the patient enrollment funnel, starting with four necessary steps. Sponsored by: OneStudyTeam |
| WhitepaperThis paper outlines various market archetypes and key considerations leaders must address when prioritizing new potential markets for gene therapies. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchWhat role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| |
|
